Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2019

View Archived Issues

Novel gamma-secretase modulators with potent in vitro and in vivo activity

DNAH17 heavy chain mutations in outer dynein arm are responsible for isolated male infertility

Researchers describe cell device for pancreatic islet transplantation without immunosuppression

PROTAC design approach for targeted degradation of BAP complex ATPAses in cancer

Inhaled alprazolam suppresses epileptiform activity in photosensitive participants with epilepsy

Deglycosylation predicts anti-PD-1/PD-L1 therapeutic efficacy

COPD has autoimmune component

BXCL-501 meets primary endpoint in phase Ib study for agitation associated with schizophrenia

Favorable safety data announced for dose-escalation run-in of phase III INTACT study

Marinus Pharmaceuticals presents data from Magnolia and Amaryllis phase II studies

Samus Therapeutics announces the launch of PU-AD clinical program

Characterization of novel RORgamma inhibitors for the treatment of autoimmune disease

Translocator protein as a microglia activation marker in early-stage AD and DLB

XC101-D13H as a promising new clinical-stage drug for the prevention of migraine

St. Jude Children's Research Hospital, CoA Therapeutics patent pantothenate kinase 3 inhibitors

New pantetheinase inhibitors discovered at Inception IBD

Nearmedic Plus describes asymmetric gossypol derivatives

BioMarin Pharmaceutical identifies hydroxyacid oxidase 1 inhibitors

GlycoMimetics discloses bifunctional inhibitors of E-selectin and galectin-3

Servier reports preclinical data on S-68890, a unique alpha7 nAChR allosteric modulator

Regulus outlines FDA requirements to reinitiate MAD studies with RGLS-4326

FDA approves rituximab biosimilar Ruxience

French ANR grant supports research to identify new targets of interest expressed by myeloid cells

Synairgen updates phase II progress with inhaled IFN-beta in patients with COPD

Gilead presents data on TLR7 agonists vesatolimod and GS-986

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...